{
    "clinical_study": {
        "@rank": "132971", 
        "arm_group": [
            {
                "arm_group_label": "Meclizine", 
                "arm_group_type": "Experimental", 
                "description": "Meclizine 25 mg, tablets"
            }, 
            {
                "arm_group_label": "Dimenhydrinate", 
                "arm_group_type": "Active Comparator", 
                "description": "Dimenhydrinate 50 mg, soft Capsgel"
            }
        ], 
        "brief_summary": {
            "textblock": "-  Evaluation of the efficacy and tolerability of Meclin (meclizine) versus Dramin\n           (Dimenhydrinate) to treat the symptoms of vertigo;\n\n        -  Evaluation of impact on quality of life in vertigo;\n\n        -  Evaluation of drowsiness caused by antihistamines used in the study;\n\n        -  Adverse event;"
        }, 
        "brief_title": "Eficacy and Tolerability of MECLIN\u00ae (Meclizine Chlorhydrate) in Acute Vertigo and Manifestations Neurovegetative", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Vertigo", 
            "Vestibular Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Vertigo", 
                "Dizziness", 
                "Vestibular Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "-  The study duration will be 15 days (visit 1, visit 2, and visit 3);\n\n        -  Symptoms of vertigo will be assessed at every visit, through a daily participant in the\n           study report the intensity of their symptoms and outcome.\n\n        -  Goal is the acquisition of data as proportion of participants with MVS= 0.5 considered\n           treatment responders, and proportion of patients with symptoms higher percentage\n           reduction of 50%"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men and Woman aged above 18 years;\n\n          -  Presence of dizziness / vertigo of vestibular origin symptons , and / or\n             neurovegetative manifestations due to peripheral vestibular disorders;\n\n          -  Participant with dizziness / vertigo of vestibular origin symptoms, show moderate\n             intensity on in 5-points Likert scale of: absent, mild , moderate , severe and very\n             severe;\n\n          -  Woman with negative Beta hcg;\n\n          -  Participants who present normal or controlled blood pressure;\n\n        Exclusion Criteria:\n\n          -  Used meclizine or dimenidrynate in 15 days;\n\n          -  Used alcohol in 48 hours;\n\n          -  Pregnancy or breastfeeding;\n\n          -  Presence of vomiting which prevent the ingestion of tablets ;\n\n          -  Presence of clinical condition that determines contraindication to the active\n             substances : convulsions , suspected intracranial compressive processes ,\n             closed-angle glaucoma , prostatic adenoma with urinary disorders , liver diseases ,\n             endocrine , renal, and / or uncontrolled cardiovascular , Parkinson's disease;\n\n          -  Participants with bladder neck obstruction or symptomatic prostatic hyperplasia :\n             anticholinergic effects of Meclizine may precipitate urinary retention;\n\n          -  a known sensitivity to hydrochloride, meclizine or dimenhydrinate;\n\n          -  Presence of malignant carcinomas or not remitted for more than 5 years;"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112578", 
            "org_study_id": "APS 002/2013", 
            "secondary_id": [
                "BRA13APS002-2014", 
                "U1111-1149-6768"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Meclizine", 
                "description": "25 mg, 3 times per day for 15 days", 
                "intervention_name": "Meclizine", 
                "intervention_type": "Drug", 
                "other_name": "Meclin"
            }, 
            {
                "arm_group_label": "Dimenhydrinate", 
                "description": "50 mg, 3 times per day for 15 days", 
                "intervention_name": "Dimenhydrinate", 
                "intervention_type": "Drug", 
                "other_name": "Dramin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Meclizine", 
                "Dimenhydrinate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Vertigo, Meclizine", 
        "lastchanged_date": "April 10, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Alexandre Gasperin, MD", 
                    "phone": "55 41 3094-5751"
                }, 
                "facility": {
                    "address": {
                        "city": "Curitiba", 
                        "country": "Brazil", 
                        "state": "Parana", 
                        "zip": "80610-010"
                    }, 
                    "name": "IPO - Parana Otorhinolaryngology Institute"
                }, 
                "investigator": {
                    "last_name": "Alexandre Gasperin, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fernando Ganan\u00e7a, PhD", 
                    "phone": "55115539-5378"
                }, 
                "facility": {
                    "address": {
                        "city": "S\u00e3o Paulo", 
                        "country": "Brazil", 
                        "zip": "04039-032"
                    }, 
                    "name": "Otorhinolaryngology Department of Federal University of S\u00e3o Paulo"
                }, 
                "investigator": {
                    "last_name": "Fernando Ganan\u00e7a, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "Eficacy and Tolerability of MECLIN\u00ae (Meclizine Chlorhydrate) in Acute Vertigo and Manifestations Neurovegetative", 
        "other_outcome": {
            "description": "Evaluation of somnolence (baseline measurement)", 
            "measure": "Stanford Sleepiness and Epworth", 
            "safety_issue": "No", 
            "time_frame": "15 days"
        }, 
        "overall_contact": {
            "email": "cristiane.lima@apsen.com.br", 
            "last_name": "Cristiane Lima", 
            "phone": "55 11 5644-8200", 
            "phone_ext": "8269"
        }, 
        "overall_official": {
            "affiliation": "Federal University of S\u00e3o Paulo", 
            "last_name": "Fernando Ganan\u00e7a, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Evaluation of efficacy by varying the Media Vertigo score (MVS) which is the average of the intensities of vertigo symptoms described at Visit 1, assigning the scores to 0-4 categories None, Mild, Moderate, Strong, Very Strong, respectively. The primary hypothesis is the non-inferiority of Meclizine chlorhydrate regarding Dimenidrinato in reducing the MVS V1 to V2.", 
            "measure": "Media Vertigo score (MVS)", 
            "safety_issue": "No", 
            "time_frame": "15 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112578"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Evaluation of impact of dizziness on quality of life DHI", 
            "measure": "Dizziness Handicap Inventory (Brazilian version)", 
            "safety_issue": "No", 
            "time_frame": "15 days"
        }, 
        "source": "Apsen Farmaceutica S.A.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Apsen Farmaceutica S.A.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}